Bio-Techne Corporation

EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST

by

Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study of more than 1,000 patients … Read more

BIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

by

MINNEAPOLIS, May 12, 2023 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 2:35 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar … Read more